



CS/NSE&BSE/UFR/2018-19
February 5, 2019

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Stock Code: SUVEN–EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 530239

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 5th February, 2019, has taken on record the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2018 and approved the following matters.

1) Interim Dividend

- a) The Board declared an interim dividend of Rs. 1.50 per equity share of face value Rs 1/- each for the year 2018-2019.
- b) The Board approved the **Record Date i.e., 15th February 2019** notified by the Company for the purpose of payment of interim dividend to the eligible shareholders.
- c) The above said dividend will be paid on and from **25th February, 2019**.

2) Re-appointment of independent directors

Based on the recommendation of the Nomination and Remuneration Committee, considered and approved the reappointment of Mr. M. Gopalakrishna, Mr. D. G. Prasad and Mr. M. R. Naidu as an Independent Directors for the second term from April 1, 2019 to March 31, 2024, subject to shareholders' approval.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

Mr. M. Gopalakrishna, Mr. D. G. Prasad and Mr. M. R. Naidu have no relationship with any member of the Board of directors. Their brief profiles are attached hereto as **Annexure – A.**

- 3) Approved the postal ballot notice which entails the following resolutions to be passed by shareholders:
- Re-appointment of M. Gopalakrishna, as an Independent Director
 - Re-appointment of D. G. Prasad, as an Independent Director
 - Re-appointment of M. R. Naidu, as an Independent Director
 - Appointment of J.A.S. Padmaja as an Independent Director


Shareholders whose names appear on the register of members/ list of beneficial owners as on February 8, 2019 will be considered for the purpose of voting through Postal Ballot and e-voting.

Further, we are enclosing herewith the following documents:

- a) Un-audited Financial Results under Ind AS for the quarter and nine months ended 31st December, 2018
- b) Limited Review Report of Statutory Auditors of the Company
- c) A copy of the Press Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 15:30 P.M. and concluded at 17:30 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**



K Hanumantha Rao
Company Secretary

Encl: as above

Suven Life Sciences Limited

Annexure – A - Brief Profiles of Directors

M. R. NAIDU

A distinguished scholar, Dr. M.R. Naidu is a Doctorate in Science and Graduate in Mechanical Engineering. Academic accomplishments apart, Dr. Naidu has been active in Professional Bodies like American Society of Mechanical Engineers, Planning Executives Institute and Indian Institute of Engineers.

Prior to his career at Suven's, Dr. M.R. Naidu has been the Chairman and Managing Director of Bharat Heavy Plates and Vessels Limited (BHPV) and Hindustan Machine Tools Limited (HMT) and holds a vast experience in Technical and Administrative Sectors. He has graced the position of President in The Andhra Petrochemicals Ltd and the U.B. Group.

M. GOPALAKRISHNA

A retired IAS officer and holds a Graduate degree in the Sciences and Law. He joined the Indian Administrative Services (IAS) in 1962; he worked with the Governments of Assam, Andhra Pradesh and Government of India. In 1997 he superannuated services as Chairman of Rural Electrification Corporation in the rank of Secretary to the Govt. of India.

During his eventful tenure, he was also Chairman, SCOPE, [the Standing Conference of Public Enterprises under the aegis of the Government of India. He has also been Director on several Industrial Promotion and Development Corporations and Manufacturing companies in the Government of India, Government of A.P. and Government of Assam.

With a career spanning nearly over 5 decades, Mr. M. Gopalakrishna adorns the Suven board with his vast administrative, corporate and managerial experience in Public Sector entities in the areas of promotion, development and regulation of industry and power utilities.

D. G. PRASAD

A financial expert, Mr. Prasad has been a career banker for over 33 years and holds hard core expertise in trade finance, international finance, merchant banking, corporate strategies, mergers and acquisitions, loan syndications, forfeiting, international negotiations and co-financing with multilateral agencies. He has been trained in —Treasury Management' at Credit Suisse, Switzerland;—International Banking and Development' at the International Development Ireland at Dublin and London and —Advanced Agribusiness Management' at Cornell University, Ithaca, New York, USA. He has also been a guest faculty at business schools on international finance and international marketing. His career is also marked by service in Canara Bank and Exim Bank.

J.A.S. PADMAJA

Smt. J.A.S. Padmaja aged 56 years is a Psychology graduate from St. Francis College Hyderabad and a post graduate Diploma in Marriage and Family Counseling from Osmania University.

She is involved in various social service activities for over 3 decades. She is a practicing counselor for the last twenty years working with mental disorders, adolescent crisis, depression and anxiety disorders and marriage counseling.

She is also associated with skill development programs for women and educated youth requiring further skills to make them employable from this backward area through this Trust.

Suven Life Sciences Limited



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvenc.com website: www.suvenc.com CIN:
L24110TG1989PLC009713

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st DEC-2018

All amounts in Indian Rupees in Lakhs

Sl. No.	Particulars	For the Quarter Ended			For the Nine Months Ended		For the year Ended
		31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	Revenue from operations	12,902.10	8,952.18	16,365.73	41,020.50	41,153.51	62,525.84
	Other Income	576.20	658.63	328.95	2,047.60	1,404.47	2,327.07
	Total income	13,478.30	9,610.81	16,694.68	43,068.10	42,557.98	64,852.91
2	Expenses						
	a) Cost of materials consumed	6,217.04	4,102.39	5,104.86	14,178.73	13,006.52	17,490.30
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,434.32)	(3,525.10)	(185.72)	(4,363.60)	(3,602.25)	(2,120.13)
	d) Employee benefits expense	1,495.42	1,398.33	1,481.60	4,608.57	4,315.58	5,873.50
	e) Finance costs	52.94	59.09	115.16	218.82	335.75	461.11
	f) Depreciation and amortisation expense	560.93	556.05	541.66	1,667.79	1,594.85	2,130.99
	g) Manufacturing Exps	2,704.36	2,493.06	2,379.39	7,482.92	6,670.79	8,821.54
	h) R & D Exps	1,403.11	1,238.73	1,387.83	4,240.71	4,155.15	5,846.66
	i) Other Expenses	956.81	803.29	1,058.62	3,048.91	2,440.34	3,322.37
	Total expenses	9,956.29	7,125.84	11,883.40	31,082.85	28,916.73	41,826.34
3	Profit before exceptional items & Tax (1-2)	3,522.01	2,484.97	4,811.28	11,985.25	13,641.25	23,026.57
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	3,522.01	2,484.97	4,811.28	11,985.25	13,641.25	23,026.57
6	Tax Expenses						
	a) Current tax	697.27	513.83	1,014.68	2,460.24	2,739.56	4,756.49
	b) Deferred tax	301.47	170.17	336.78	1,316.56	1,310.07	2,427.35
7	Net Profit/ (Loss) for the period/year(5-6)	2,523.27	1,800.97	3,459.82	8,208.45	9,591.62	15,842.73
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(10.58)	(10.59)	(3.73)	(31.75)	(11.18)	(42.33)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.76	3.67	1.29	11.09	3.87	14.65
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(6.82)	(6.92)	(2.44)	(20.66)	(7.31)	(27.68)
9	Total Comprehensive Income for the period (7+8)	2,516.45	1,794.05	3,457.38	8,187.79	9,584.31	15,815.05
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Other Equity						85,397.16
12	Earning Per Share (EPS) (Face value of Rs.1/- each)						
	a) Basic	1.98	1.41	2.72	6.45	7.54	12.45
	b) Diluted	1.98	1.41	2.72	6.45	7.54	12.45
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES						
PARTICULARS	For the Quarter Ended			For the Nine Months Ended		For the year Ended
	31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1 SEGMENT REVENUE :-						
a) Manufaturing (CRAMS)	11,508.11	8,087.96	15,693.88	37,620.29	39,051.11	59,687.64
b) Services (DDDSS)	1,393.99	864.22	671.85	3,400.21	2,102.40	2,838.20
c) Research & Development	-	-	-	-	-	-
TOTAL	12,902.10	8,952.18	16,365.73	41,020.50	41,153.51	62,525.84
Less Inter segment Revenue	-	-	-	-	-	-
Net Sales from Operations	12,902.10	8,952.18	16,365.73	41,020.50	41,153.51	62,525.84
2 SEGMENT RESULTS :-						
Profit/(Loss) before tax and interest:						
a) Manufaturing (CRAMS)	4,138.53	3,252.05	6,444.25	14,477.32	17,539.24	28,031.87
b) Services (DDDSS)	785.85	440.57	267.76	1,987.56	992.37	1,428.77
c) Research & Development	(1,403.11)	(1,238.73)	(1,387.83)	(4,240.71)	(4,155.15)	(5,846.66)
TOTAL	3,521.27	2,453.89	5,324.18	12,224.17	14,376.46	23,613.98
Less: i) Interest	31.17	62.29	72.41	129.43	233.71	281.59
ii) Other Un-allocable expenditure/(Income), net	(31.91)	(93.37)	440.49	109.49	501.50	305.82
Total Profit Before Tax	3,522.01	2,484.97	4,811.28	11,985.25	13,641.25	23,026.57
3 SEGMENT ASSETS :						
a) Manufaturing (CRAMS)	64,192.57	57,618.63	56,835.94	64,192.57	56,835.94	52,557.03
b) Services (DDDSS)	5,755.22	3,767.31	4,174.47	5,755.22	4,174.47	4,061.14
c) Research & Development	2,794.09	3,028.20	3,117.69	2,794.09	3,117.69	3,031.96
d) Un allocated	41,584.05	44,219.74	35,007.49	41,584.05	35,007.49	41,234.30
TOTAL	114,325.93	108,633.88	99,135.59	114,325.93	99,135.59	100,884.43
SEGMENT LIABILITIES :						
a) Manufaturing (CRAMS)	11,305.72	9,282.73	9,663.85	11,305.72	9,663.85	8,594.07
b) Services (DDDSS)	690.10	473.46	498.66	690.10	498.66	382.64
c) Research & Development	2,071.66	1,669.94	1,866.63	2,071.66	1,866.63	1,587.28
d) Un allocated	1,053.78	949.14	856.23	1,053.78	856.23	714.79
TOTAL	15,121.26	12,375.27	12,885.37	15,121.26	12,885.37	11,278.78


1). The above financial results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 05th February, 2019 and the same reviewed by the Statutory Auditors.

2). Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.

3). The Board has declared an Interim Dividend of Rs. 1.50 per equity share (150% of face value of Rs. 1.00/- each) for the financial year 2018-19, The outflow on account of Interim dividend including dividend distribution tax is Rs. 2301.69 lakhs.

4). The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LIMITED



VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place: Hyderabad
Date: 05th February, 2019

We Deliver



Ref No.LR/SUVEN-Q3/2018-19:

LIMITED REVIEW REPORT

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying statement of Unaudited Financial Results of **SUVEN LIFE SCIENCES LIMITED**, ("the Company") having registered office at SDE Serene Chambers, 6th Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the quarter and nine months ended December 31,2018 ("The statement"), attached here with, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations,2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05, July 2016.

2. The Preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, Interim Financial reporting (IND AS 34) prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 05 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to express conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO LLP**,
Chartered Accountants
(Firm Registration No.004436S)


(RAJENDER REDDY K)
P A R T N E R
Membership No.231834



Place: Hyderabad
Date: 05/02/2019

News Release

Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December' 2018

HYDERABAD, INDIA (5th February 2019) – Suven Life Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2018. The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5th Feb' 2019 at Hyderabad

Financial Highlights for the 3rd Quarter ended December' 2018 (QoQ):

Growth in income	INR 1348 Mn vs 961 Mn - up by 40.24%
Growth in PAT	INR 252 Mn vs 179 Mn - up by 40.27%
Growth in EBIDTA	INR 413 Mn vs 310 Mn - up by 33.41%

Financial Highlights for the 9 months' period ended December' 2018 (YoY):

Growth in income	INR 4307 Mn vs 4256 Mn - up by 1.20%
Growth in PAT	INR 819 Mn vs. 958 Mn - down by 14.57%
Growth in EBIDTA	INR 1387 Mn vs 1557 Mn - down by 10.92%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 424 Mn (9.85% on revenue) for the 9 months' period ended Dec' 2018.

The Board has declared an Interim Dividend of Re.1.50 per share (150% of face value of Rs. 1.00 each).

Suven Board approved of demerger of Contract Research and Manufacturing Services undertaking of Suven Life Sciences Limited (SLSL) into Suven Pharmaceuticals Limited (SPL), through a scheme of arrangement, subject to approval of respective regulatory authorities. More details will be notified separately.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor, Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com